U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06933134) titled 'Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis' on March 25.

Brief Summary: Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.

Study Start Date: May, 2025

Study Type: OBSERVATIONAL

Condition: Rheumatoid Arthritis (RA)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: University Hospital, Tours

Published by HT Digital Content Services with permission from Health Daily Digest....